文献速递胸部肿瘤

非小细胞肺癌中免疫检查点抑制剂的降阶梯策略:我们已有足够证据吗?

De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?
PubMed 文献 · J Clin Oncol · 2025-01-21

本综述讨论非小细胞肺癌中免疫检查点抑制剂降阶梯治疗的主要问题与挑战,聚焦剂量强度降低和治疗时长选择,并评估实施降阶梯策略的经济影响。

要点

  • 免疫检查点抑制剂的药代和药效特性与传统细胞毒药物显著不同,治疗强度与结局的直接关系证据有限。
  • 降阶梯策略包括减少剂量、缩短疗程和降低给药频率,可能优化疗效、减少毒性、改善生活质量并降低成本。
  • 降阶梯策略最终可能有助于减少治疗不平等并改善全球药物可及性。

核心结论

  • 降阶梯治疗通过减少免疫检查点抑制剂的剂量、时长和给药频率,可能优化疗效、减少毒性、改善生活质量并降低成本,最终有助于减少治疗不平等和改善全球药物可及性。

研究设计与样本

  • 本综述旨在总结和讨论非小细胞肺癌患者中免疫检查点抑制剂降阶梯的主要问题和挑战,聚焦剂量强度降低和治疗时长选择,并评估实施降阶梯策略的经济影响。

主要发现

  • 目前一刀切的最大化方案被认为是标准治疗,免疫检查点抑制剂按固定剂量给药而不论患者体重。
  • 免疫检查点抑制剂的治疗时长在各分期之间往往任意,从固定时间点至疾病进展或不可接受的毒性不等。
  • 基于最大耐受量的已批准和选定剂量常被高估,因支持治疗强度与结局直接关系的证据有限。
  • 这可能导致患者过度治疗,增加毒性风险而无疗效增强。
  • 这些药物的使用与显著成本相关,给全球医疗系统带来负担并加剧护理可及性差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, with ICBs administered at flat doses regardless of patients' weight. Treatment duration with ICBs is often arbitrary across stages, ranging from a fixed time point to until disease progression or unacceptable toxicity. However, the pharmacokinetic and pharmacodynamic properties of ICBs differ significantly from those of traditional cytotoxic drugs and the approved and selected doses on the basis of the maximum tolerated dose are often overestimated as there is limited evidence supporting a direct relationship between therapeutic intensity and outcomes. This can lead to overtreatment of patients, resulting in an increased risk of toxicity without enhanced efficacy. In addition, the use of these drugs is associated with significant costs that burden the global health care system and exacerbate disparities in access to care. De-escalating treatment by reducing the dose, duration, and frequency of administration of ICBs could optimize treatment efficacy, reduce toxicities, improve patients' quality of life, and even decrease costs. Ultimately, de-escalation strategies may help to reduce treatment inequalities and to improve drug access worldwide. The aim of this review is to summarize and discuss the main issues and challenges regarding the de-escalation of ICBs in patients with NSCLC, focusing on dose-intensity reduction and treatment duration selection. Moreover, we assess the economic impact of implementing de-escalation approaches.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Remon J, Bortolot M, Bironzo P, et al. De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence? J Clin Oncol. 2025. PMID: 39836933. doi:10.1200/JCO-24-02347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。